Literature DB >> 24303922

Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.

Li Zhu1, Takamichi Ito, Takeshi Nakahara, Konosuke Nagae, Yoko Fuyuno, Masayoshi Nakao, Maki Akahoshi, Rieko Nakagawa, Yating Tu, Hiroshi Uchi, Masutaka Furue.   

Abstract

S100P is a member of the S100 family. Increased levels of S100P have been documented in various malignancies. Binding of extracellular S100P to receptor for advanced glycation end products (RAGE) or coupling of intracellular S100P with a cytoskeletal protein, ezrin, play a crucial role in tumor growth, invasion and metastasis. However, little is known about the expression of S100P, RAGE and ezrin in malignant melanoma. We immunostained these three molecules in 20 primary and 20 metastatic melanomas. Samples of 20 benign nevus pigmentosus and 10 of normal skin were tested as controls. The expression levels (percentage of positively stained cells) of S100P, RAGE and ezrin were significantly higher in melanomas than in nevus pigmentosus. Moreover, slightly but significantly higher expression levels were observed in metastatic than in primary melanomas. Significant positive correlations were evident between the expression levels of S100P and RAGE, S100P and ezrin, and RAGE and ezrin, respectively. In conclusion, the coordinate upregulation of S100P, RAGE and ezrin may possibly facilitate malignant transformation of melanoma.
© 2013 Japanese Dermatological Association.

Entities:  

Keywords:  S100P; ezrin; malignant melanoma; receptor for advanced glycation end products

Mesh:

Substances:

Year:  2013        PMID: 24303922     DOI: 10.1111/1346-8138.12323

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  10 in total

1.  The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults.

Authors:  Iwona Lugowska; Ewa Mierzejewska; Malgorzata Lenarcik; Teresa Klepacka; Irena Koch; Elzbieta Michalak; Katarzyna Szamotulska
Journal:  Tumour Biol       Date:  2016-05-20

Review 2.  Ousting RAGE in melanoma: A viable therapeutic target?

Authors:  Deeba N Syed; Ahmed Aljohani; Durdana Waseem; Hasan Mukhtar
Journal:  Semin Cancer Biol       Date:  2017-10-24       Impact factor: 15.707

Review 3.  The life and works of S100P - from conception to cancer.

Authors:  Filip Prica; Tomasz Radon; Yuzhu Cheng; Tatjana Crnogorac-Jurcevic
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

4.  Role of miR-647 in human gastric cancer suppression.

Authors:  Wenlong Cao; Weiyuan Wei; Zexu Zhan; Dongyi Xie; Yubo Xie; Qiang Xiao
Journal:  Oncol Rep       Date:  2017-01-17       Impact factor: 3.906

5.  BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.

Authors:  Atte A Manninen; Maria Gardberg; Susanna Juteau; Suvi Ilmonen; Joonas Jukonen; Noora Andersson; Olli Carpén
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

6.  Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming.

Authors:  Xinyue Wang; Nan Li; Anna Han; Yixuan Wang; Zhenhua Lin; Yang Yang
Journal:  Cancer Sci       Date:  2020-09-18       Impact factor: 6.716

Review 7.  RAGE Signaling in Melanoma Tumors.

Authors:  Olamide T Olaoba; Sultan Kadasah; Stefan W Vetter; Estelle Leclerc
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 8.  Role of Biomarkers in the Integrated Management of Melanoma.

Authors:  Piyu Parth Naik
Journal:  Dis Markers       Date:  2021-12-30       Impact factor: 3.434

Review 9.  The Role of Calcium Signaling in Melanoma.

Authors:  Haoran Zhang; Zhe Chen; Aijun Zhang; Anisha A Gupte; Dale J Hamilton
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

10.  S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer.

Authors:  Ya-Ling Hsu; Jen-Yu Hung; Yung-Yu Liang; Yi-Shiuan Lin; Ming-Ju Tsai; Shah-Hwa Chou; Chi-Yu Lu; Po-Lin Kuo
Journal:  Oncotarget       Date:  2015-10-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.